22 April 2022 -
SHS and yabeo invest in the leading Scandinavian digital health platform Dr.Dropin
- The fast-growing Norwegian healthcare provider Dropin enables short-term medical consultation and treatment – in person on site as well as digitally via app
- Dropin posted revenue of more than 30m EUR in 2021, constituting a CAGR of more than 100% for the last three years
- SHS invests from its fifth fund generation in the Scandinavian company with the aim to expand Dr.Dropin’s service offering into other European countries
Tübingen / Oslo 22.04.2022
The Tübingen-based investment company SHS invests together with the Munich-based investor yabeo in Dr.Dropin, a digital + physical healthcare provider platform for medical consultations – physically on site at one of the Dr.Dropin clinics or in the form of a digital consultation via app.
In times of the corona pandemic, but also before, patients suffer from long waiting times until they get an appointment with a doctor. Independent it is an appointment with a general practitioner or a specialist – the waiting times are long and the patient journeys often challenging. Dr.Dropin would like to eliminate these difficulties with its bundle of clinics. Appointments are easily booked online via the company’s own app. Patients should thus be able to be treated at short notice without long waiting times either in person or via digital consultation hours. Follow-up appointments can also take place easily within the digital set-up.
In this way, Dr.Dropin combines the personal contact that is essential in medical consultations with the advantages digital products have in order to make patients’ journeys easier in their everyday lives.
As part of the investment strategy,Dr. Dropin wants, based on the success in Norway, to expand its services into other European countries. SHS supports the company in its expansion and sees Dr. Dropin’s patient offering as a competitive advantage that promises great growth potential.
“We are delighted to have SHS on board on our exciting journey towards internationalisation and to have an investor with sector expertise and vision. Our goal is to make healthcare better and easily accessible to everyone,” says Dr.Dropin CEO Daniel Sørli.
“SHS is pleased to be able to support a company like Dr.Dropin. Nowadays, a straightforward and fully comprehensive medical offer with the possibility of digital consultation is essential. We think that Dr.Dropin’s “digiphysical” concept fills a promising gap in the market and we are pleased to be able to support the company with our know-how and many years of experience in the healthcare sector. We are always seeking for promising companies that have the potential to become European healthcare champions like Dr.Dropin,” explains SHS partner Dr. Cornelius Maas.
Dr. Gerrit Seidel, Managing Director, and Partner at Yabeo comments: “We are always looking for innovative and disruptive healthtech companies to invest in, and Dr.Dropin fits our profile well. With the growth and development shown by Dr.Dropin and their highly dedicated team so far, combined with our goal of investing in companies that are game changers within their industry, we believe this transaction will contribute to Dr.Dropins competitive growth when entering the European markets”.
The Norwegian healthcare provider Dr.Dropin was founded in 2017 by Dr Daniel Sørli. The company offers general practitioners, specialists, physiotherapists and psychologists at fixed prices with short waiting times. The company has 25 clinics in all major Norwegian cities and also offers most of its services via secure digital solutions. The company’s largest shareholders are the start-up Askeladden & Co and the founder Dr Daniel Sørli himself.
Further information at www.drdropin.no.
About SHS Capital:
“Building European Healthcare Champions” is the guiding principle of the Tübingen-based sector investor SHS. With this in mind, the investor specialising in healthcare investments finances and develops its portfolio companies. Since its foundation in 1993, the focus of its investments has been on expansion financing, shareholder changes and succession situations. In doing so, SHS takes both minority and majority stakes. Investors in SHS funds include pension funds, funds of funds, family offices, entrepreneurs, strategic investors and the SHS management team. The equity investment of the AIFM-registered company is up to EUR 20 million. Volumes exceeding this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ethical aspects. The investment company is committed to the principle of Socially Responsible Investing (SRI) and is a member of UNPRI, an investor initiative launched by the UN Environment Programme. Its members contractually agree to comply with ecological and social guidelines in their investments. SHS portfolio companies include, for example, Phenox GmbH from Bochum, which specialises in stroke treatment, the drug delivery expert Develco Pharma AG, which is based in Switzerland and Germany, and the Dutch growth company Salvia BioElectronics B.V., which uses minimally invasive neurostimulation to treat neurological diseases. SHS is currently investing from its fifth fund, which was launched in 2018.
Further information at www.shs-capital.eu
yabeo is a venture investment and advisory firm that invests in and sustainably develops early-stage technology companies. yabeo’s success lies in growing companies, scaling organisations and rolling out new technologies. The investment focus of the Munich-based venture capitalist is on innovative FinTechs (e.g. Solarisbank), InsurTechs (e.g. CLARK) and HealthTechs (e.g. CERA). yabeo currently manages assets under management of more than EUR 200 million across all investment platforms. The objective is to invest in early-stage technology-driven companies that are driving change in their segment by redefining previous rules of the game through new technology and innovative business models.
Further information at www.yabeo.de